vs
Side-by-side financial comparison of CARTERS INC (CRI) and PERRIGO Co plc (PRGO). Click either name above to swap in a different company.
PERRIGO Co plc is the larger business by last-quarter revenue ($1.1B vs $757.8M, roughly 1.5× CARTERS INC). CARTERS INC runs the higher net margin — 1.5% vs -127.8%, a 129.3% gap on every dollar of revenue. On growth, CARTERS INC posted the faster year-over-year revenue change (-0.1% vs -2.5%). PERRIGO Co plc produced more free cash flow last quarter ($148.6M vs $-144.1M).
Carter's, Inc. is a major American designer and marketer of children's apparel. It was founded in 1865 by William Carter.
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...
CRI vs PRGO — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $757.8M | $1.1B |
| Net Profit | $11.6M | $-1.4B |
| Gross Margin | 45.1% | 32.6% |
| Operating Margin | 3.8% | -116.0% |
| Net Margin | 1.5% | -127.8% |
| Revenue YoY | -0.1% | -2.5% |
| Net Profit YoY | -80.1% | -3093.9% |
| EPS (diluted) | $0.32 | $-10.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $1.1B | ||
| Q3 25 | $757.8M | $1.0B | ||
| Q2 25 | $585.3M | $1.1B | ||
| Q1 25 | $629.8M | $1.0B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $1.1B |
| Q4 25 | — | $-1.4B | ||
| Q3 25 | $11.6M | $7.5M | ||
| Q2 25 | $446.0K | $-8.4M | ||
| Q1 25 | $15.5M | $-6.4M | ||
| Q4 24 | — | $-44.4M | ||
| Q3 24 | — | $-21.0M | ||
| Q2 24 | — | $-108.4M | ||
| Q1 24 | — | $2.0M |
| Q4 25 | — | 32.6% | ||
| Q3 25 | 45.1% | 36.1% | ||
| Q2 25 | 48.1% | 34.4% | ||
| Q1 25 | 46.2% | 37.6% | ||
| Q4 24 | — | 33.9% | ||
| Q3 24 | — | 37.2% | ||
| Q2 24 | — | 37.0% | ||
| Q1 24 | — | 33.1% |
| Q4 25 | — | -116.0% | ||
| Q3 25 | 3.8% | 7.0% | ||
| Q2 25 | 0.7% | 4.3% | ||
| Q1 25 | 4.1% | 4.5% | ||
| Q4 24 | — | 10.0% | ||
| Q3 24 | — | 7.4% | ||
| Q2 24 | — | -2.5% | ||
| Q1 24 | — | -5.1% |
| Q4 25 | — | -127.8% | ||
| Q3 25 | 1.5% | 0.7% | ||
| Q2 25 | 0.1% | -0.8% | ||
| Q1 25 | 2.5% | -0.6% | ||
| Q4 24 | — | -3.9% | ||
| Q3 24 | — | -1.9% | ||
| Q2 24 | — | -10.2% | ||
| Q1 24 | — | 0.2% |
| Q4 25 | — | $-10.23 | ||
| Q3 25 | $0.32 | $0.05 | ||
| Q2 25 | $0.01 | $-0.06 | ||
| Q1 25 | $0.43 | $-0.05 | ||
| Q4 24 | — | $-0.32 | ||
| Q3 24 | — | $-0.15 | ||
| Q2 24 | — | $-0.79 | ||
| Q1 24 | — | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $184.2M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $864.6M | $2.9B |
| Total Assets | $2.5B | $8.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | $184.2M | $432.1M | ||
| Q2 25 | $338.2M | $454.2M | ||
| Q1 25 | $320.8M | $409.9M | ||
| Q4 24 | — | $558.8M | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $542.8M | ||
| Q1 24 | — | $658.5M |
| Q4 25 | — | $2.9B | ||
| Q3 25 | $864.6M | $4.4B | ||
| Q2 25 | $853.9M | $4.5B | ||
| Q1 25 | $847.2M | $4.4B | ||
| Q4 24 | — | $4.3B | ||
| Q3 24 | — | $4.6B | ||
| Q2 24 | — | $4.5B | ||
| Q1 24 | — | $4.7B |
| Q4 25 | — | $8.5B | ||
| Q3 25 | $2.5B | $10.1B | ||
| Q2 25 | $2.5B | $10.1B | ||
| Q1 25 | $2.3B | $9.8B | ||
| Q4 24 | — | $9.6B | ||
| Q3 24 | — | $11.2B | ||
| Q2 24 | — | $10.4B | ||
| Q1 24 | — | $10.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-128.0M | $175.4M |
| Free Cash FlowOCF − Capex | $-144.1M | $148.6M |
| FCF MarginFCF / Revenue | -19.0% | 13.4% |
| Capex IntensityCapex / Revenue | 2.1% | 2.4% |
| Cash ConversionOCF / Net Profit | -11.04× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $145.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $175.4M | ||
| Q3 25 | $-128.0M | $51.7M | ||
| Q2 25 | $40.3M | $75.9M | ||
| Q1 25 | $-48.6M | $-64.5M | ||
| Q4 24 | — | $312.6M | ||
| Q3 24 | — | $42.2M | ||
| Q2 24 | — | $9.5M | ||
| Q1 24 | — | $-1.4M |
| Q4 25 | — | $148.6M | ||
| Q3 25 | $-144.1M | $29.8M | ||
| Q2 25 | $24.1M | $56.7M | ||
| Q1 25 | $-59.0M | $-90.0M | ||
| Q4 24 | — | $274.9M | ||
| Q3 24 | — | $15.1M | ||
| Q2 24 | — | $-18.9M | ||
| Q1 24 | — | $-26.5M |
| Q4 25 | — | 13.4% | ||
| Q3 25 | -19.0% | 2.9% | ||
| Q2 25 | 4.1% | 5.4% | ||
| Q1 25 | -9.4% | -8.6% | ||
| Q4 24 | — | 24.2% | ||
| Q3 24 | — | 1.4% | ||
| Q2 24 | — | -1.8% | ||
| Q1 24 | — | -2.4% |
| Q4 25 | — | 2.4% | ||
| Q3 25 | 2.1% | 2.1% | ||
| Q2 25 | 2.8% | 1.8% | ||
| Q1 25 | 1.6% | 2.4% | ||
| Q4 24 | — | 3.3% | ||
| Q3 24 | — | 2.5% | ||
| Q2 24 | — | 2.7% | ||
| Q1 24 | — | 2.3% |
| Q4 25 | — | — | ||
| Q3 25 | -11.04× | 6.89× | ||
| Q2 25 | 90.37× | — | ||
| Q1 25 | -3.13× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -0.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CRI
| Sales Channel Directly To Consumer | $362.3M | 48% |
| Sales Channel Through Intermediary | $283.8M | 37% |
| Other | $110.4M | 15% |
| Gift Cards | $1.3M | 0% |
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
